Literature DB >> 11833079

Anti-HBV hairpin ribozyme-mediated cleavage of target RNA in vitro.

Yu-Hu Song1, Ju-Sheng Lin, Nan-Zhi Liu, Xin-Juan Kong, Na Xie, Nan-Xia Wang, You-Xin Jin, Kuo-Huan Liang.   

Abstract

AIM: To study the preparation and cleavage activity of HpRz directed against the transcript of HBV core gene in vitro.
METHODS: HpRz gene designed by computer targeting the transcript of HBV core gene was cloned into the vector p1.5 between 5'-cis-Rz and 3'-cis-Rz. 32p-labeled HpRz transcript proved whether the vector fit for the preparation of hairpin ribozyme in vitro. 32p-labeled pKC transcript containing HBV core region as target-RNA was transcribed using T7 RNA polymerase and purified by denaturing PAGE. Cold HpRz transcript was incubated with 32p-labeled target-RNAs under different conditions and radio autographed after denaturing polyacrylamide gel electrophoresis.
RESULTS: HpRz has the specific ability of cleavage of target RNA at 37 degrees and 12 mM MgCl2. Km=26.31 nmol/L, Kcat=0.18/min. These results revealed that the design of HpRz was correct.
CONCLUSION: HpRz prepared in this study possesses specific catalytic activity from the identification of cleavage activity. These results indicate that hairpin ribozyme may intracellularly inhibit the replication of HBV, therefore it may become a novel potent weapon for the treatment of hepatitis B.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11833079      PMCID: PMC4656634          DOI: 10.3748/wjg.v8.i1.91

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  39 in total

1.  Retrovirally expressed anti-HIV ribozymes confer a selective survival advantage on CD4+ T cells in vitro.

Authors:  C Klebba; O G Ottmann; M Scherr; M Pape; J W Engels; M Grez; D Hoelzer; S A Klein
Journal:  Gene Ther       Date:  2000-03       Impact factor: 5.250

2.  The antisense sequence of the HIV-1 TAR stem-loop structure covalently linked to the hairpin ribozyme enhances its catalytic activity against two artificial substrates.

Authors:  M Pérez-Ruiz; D Sievers; P A García-López; A Berzal-Herranz
Journal:  Antisense Nucleic Acid Drug Dev       Date:  1999-02

3.  Preliminary results of Thymosin-a1 versus interferon-alpha-treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B.

Authors:  L Zhuang; J You; B Z Tang; S Y Ding; K H Yan; D Peng; Y M Zhang; L Zhang
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

4.  Gene therapy targeting cord blood-derived CD34+ cells from HIV-exposed infants: preclinical studies.

Authors:  X Li; A Gervaix; D Kang; P Law; S A Spector; A D Ho; F Wong-Staal
Journal:  Gene Ther       Date:  1998-02       Impact factor: 5.250

5.  [Preparation and identification of hammerhead ribozyme in vitro against rat caspase-3 mRNA fragment].

Authors:  R Xu; X Zhou; Q Xie; Y Jin; D Liao
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2000-12

6.  Activity identification of anti-caspase-3 mRNA hammerhead ribozyme in both cell-free condition and BRL-3A cells.

Authors:  R Xu; J Liu; X Zhou; Q Xie; Y Jin; H Yu; D Liao
Journal:  Chin Med J (Engl)       Date:  2001-06       Impact factor: 2.628

Review 7.  Chinese medicinal herbs for chronic hepatitis B: a systematic review.

Authors:  J Liu; H McIntosh; H Lin
Journal:  Liver       Date:  2001-08

Review 8.  Chronic hepatitis B virus infection: treatment strategies for the next millennium.

Authors:  A H Malik; W M Lee
Journal:  Ann Intern Med       Date:  2000-05-02       Impact factor: 25.391

Review 9.  Hepatitis B.

Authors:  A S Befeler; A M Di Bisceglie
Journal:  Infect Dis Clin North Am       Date:  2000-09       Impact factor: 5.982

10.  Cleavage of hepatitis B virus RNA by three ribozymes transcribed from a single DNA template.

Authors:  F von Weizsäcker; H E Blum; J R Wands
Journal:  Biochem Biophys Res Commun       Date:  1992-12-15       Impact factor: 3.575

View more
  6 in total

1.  Investigation of HGV and TTV infection in sera and saliva from non-hepatitis patients with oral diseases.

Authors:  Jie Yan; Li-Li Chen; Yong-Liang Lou; Xiao-Zhi Zhong
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

2.  Maxizyme-mediated specific inhibition on mutant-type p53 in vitro.

Authors:  Xin-Juan Kong; Yu-Hu Song; Ju-Sheng Lin; Huan-Jun Huang; Nan-Xia Wang; Nan-Zhi Liu; Bin Li; You-Xin Jin
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

3.  Targeted ribonuclease can inhibit replication of hepatitis B virus.

Authors:  Jun Liu; Ying-Hui Li; Cai-Fang Xue; Jin Ding; Wei-Dong Gong; Ya Zhao; Yu-Xiao Huang
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

4.  Inhibition of HBV targeted ribonuclease enhanced by introduction of linker.

Authors:  Wei-Dong Gong; Jun Liu; Jin Ding; Ya Zhao; Ying-Hui Li; Cai-Fang Xue
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

5.  Anti-HBV effect of TAT- HBV targeted ribonuclease.

Authors:  Jin Ding; Jun Liu; Cai-Fang Xue; Wei-Dong Gong; Ying-Hui Li; Ya Zhao
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

Review 6.  Progress and Prospects of Anti-HBV Gene Therapy Development.

Authors:  Mohube B Maepa; Ilke Roelofse; Abdullah Ely; Patrick Arbuthnot
Journal:  Int J Mol Sci       Date:  2015-07-31       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.